Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors-Reference-Cited by-同舟云学术

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

Published:2015-08-10 Issue:9 Volume:38 Page:1638-1642
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Rosenstock Julio¹,Ferrannini Ele²

Affiliation:

1. Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX

2. Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/38/9/1638/625128/dc151380.pdf

Reference22 articles.

1. U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 15 May 2015. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf. Accessed 22 June 2015

2. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined [Internet], 12 June 2015. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf. Accessed 22 June 2015

3. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program;Erondu;Diabetes Care,2015

4. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition;Peters;Diabetes Care,2015

5. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial;Perkins;Diabetes Care,2014

Cited by 518 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

2. SGLT-2i associated diabetic ketoacidosis in the setting of cardiogenic shock;BMJ Case Reports;2024-09

3. SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials;Breast Cancer Research and Treatment;2024-08-23

4. GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-22

5. Diagnostik und Therapie der Diabetischen Ketoazidose bei Erwachsenen;Journal für Endokrinologie, Diabetologie und Stoffwechsel;2024-08-19